Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis

National Institute for Health and Care Excellence.Psoriasis: assessment and management. Systemic therapy. Available at:www.nice.org.uk/guidance/cg153/chapter/1‐recommendations#systemic‐therapy(last accessed 16 June 2020).

[5]

10.1016/j.jaad.2018.11.057

[6]

10.1080/09546634.2017.1402116

[7]

10.1136/bmj.j3932

[8]

10.1016/j.jaad.2018.02.027

[9]

10.1371/journal.pone.0220868

[10]

10.1111/jdv.15277

[11]

Bai F "Short‐term efficacy and safety of IL‐17, IL‐12/23, and IL‐23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta‐analysis of randomized controlled trials" J Immunol Res (2019)

[12]

Sbidian E "Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis" Cochrane Database Syst Rev (2017)

[13]

Sbidian E "Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis" Cochrane Database Syst Rev (2020)

[14]

10.1016/j.jphs.2018.12.006

[15]

Geng W "Efficacy of several biological therapies for treating moderate to severe psoriasis: a network meta‐analysis" Exp Ther Med (2018)

[16]

10.1007/s13555-019-00337-y

[17]

10.1111/bjd.14814

[18]

10.1016/j.jid.2017.04.009

[19]

10.1016/j.jaad.2019.12.038

[20]

10.1371/journal.pone.0076654

[21]

10.1111/bjd.15665

[22]

10.1111/bjd.19039

[23]

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

Brian Hutton, Georgia Salanti, Deborah M. Caldwell et al.

Annals of Internal Medicine 10.7326/m14-2385

[24]

10.1111/bjd.18333

[25]

10.1177/1536867x1101100206

[26]

HigginsJPT ThomasJ ChandlerJet al.Cochrane Handbook for Systematic Reviews of Interventions version 6.0Available at:www.training.cochrane.org/handbook(last accessed 16 June 2020).

[27]

10.1016/j.ddtec.2016.09.004

[28]

European Medicines Agency.Assessment report: Taltz procedure no. EMEA/H/C/003943/0000. Available at:www.ema.europa.eu/en/documents/assessment‐report/taltz‐epar‐public‐assessment‐report_en.pdf(last accessed 16 June 2020).

[29]

European Medicines Agency.Assessment report: Cosentyx procedure no. EMEA/H/C/003729. Available at:www.ema.europa.eu/en/documents/assessment‐report/cosentyx‐epar‐public‐assessment‐report_en.pdf(last accessed 16 June 2020).

[30]

US Food and Drug Administration.Application number 125504Orig1s000. Office director memo: Cosentyx. Available at:www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125504Orig1s000ODMemo.pdf(last accessed 16 June 2020).

[31]

European Medicines Agency.Assessment report: Ilumetri procedure no. EMEA/H/C/004514/0000. Available at:www.ema.europa.eu/en/documents/assessment‐report/ilumetri‐epar‐public‐assessment‐report_en.pdf(last accessed 16 June 2020).

[32]

European Medicines Agency.Assessment report: Skyrizi procedure no. EMEA/H/C/004759/0000. Available at:www.ema.europa.eu/en/documents/assessment‐report/skyrizi‐epar‐public‐assessment‐report_en.pdf(last accessed 16 June 2020).

[33]

US Food and Drug Administration.Application number 761061Orig1s000. Multi‐discipline review: Tremfya. Available at:www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761061Orig1s000MultidisciplineR.pdf(last accessed 16 June 2020).

[34]

Moller AH "A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ‐5D‐derived utility values" Patient Relat Outcome Meas (2015)

[35]

10.1111/bjd.17036

[36]

10.1001/jamadermatol.2019.1783

[37]

10.1016/j.jid.2018.07.028

[38]

10.1016/s0140-6736(19)31773-8

[39]

10.1016/j.jaci.2018.11.038

[40]

10.1111/j.1365-2133.2012.10835.x

[41]

10.1016/s0140-6736(14)61122-3

Cited By

81

European Guideline on Chronic Pruritus. In cooperation with the European Dermatology Forum (EDF)

Elke Weisshaar, Simon Müller · 2025

Acta Dermato-Venereologica

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

Yuxiong Jiang, Youdong Chen · 2023

BioDrugs

Soluble Factors and Receptors Involved in Skin Innate Immunity—What Do We Know So Far?

Lucian G. Scurtu, Olga Simionescu · 2021

Biomedicines

Metrics

81

Citations

41

References

Details

Published: Aug 09, 2020
Vol/Issue: 183(4)
Pages: 638-649
License: View

Authors

S

S.K. Mahil

St John’s Institute of Dermatology Guy’s and St Thomas’ NHS Foundation Trust London SE1 9RT UK

M

M.C. Ezejimofor

British Association of Dermatologists London W1T 5HQ UK

L

L.S. Exton

British Association of Dermatologists London W1T 5HQ UK

L

L. Manounah

British Association of Dermatologists London W1T 5HQ UK

A

A.D. Burden

Institute of Infection, Immunity and Inflammation University of Glasgow Glasgow G12 8QQ UK

L

L.C. Coates

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford Oxford OX3 7LD UK

M

M. Brito

St John’s Institute of Dermatology Guy’s and St Thomas’ NHS Foundation Trust London SE1 9RT UK

A

A. McGuire

St John’s Institute of Dermatology Guy’s and St Thomas’ NHS Foundation Trust London SE1 9RT UK

R

R. Murphy

Department of Dermatology Sheffield Teaching Hospitals NHS Foundation Trust Sheffield S10 2JF UK; Department of Dermatology Sheffield Children’s NHS Foundation Trust Sheffield S10 3FL UK; University of Nottingham University Park Nottingham NG7 2RD UK

C

C.M. Owen

Department of Dermatology East Lancashire Hospitals NHS Trust Burnley BB10 2PQ UK

R

R. Parslew

Department of Dermatology Liverpool University Hospitals NHS Foundation Trust Liverpool L7 8XP UK

R

R.T. Woolf

St John’s Institute of Dermatology Guy’s and St Thomas’ NHS Foundation Trust London SE1 9RT UK

Z

Z.Z.N. Yiu

Dermatology Centre Salford Royal NHS Foundation Trust The University of Manchester Manchester Academic Health Science Centre NIHR Manchester Biomedical Research Centre Manchester M13 9PT UK

O

O.A. Uthman

Warwick Centre for Applied Health Research and Delivery Division of Health Sciences Warwick Medical School University of Warwick Coventry CV4 7AL UK

M

M.F. Mohd Mustapa

British Association of Dermatologists London W1T 5HQ UK

C

C.H. Smith

St John’s Institute of Dermatology Guy’s and St Thomas’ NHS Foundation Trust London SE1 9RT UK

Funding

British Association of Dermatologists

Cite This Article

S.K. Mahil, M.C. Ezejimofor, L.S. Exton, et al. (2020). Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis. British Journal of Dermatology, 183(4), 638-649. https://doi.org/10.1111/bjd.19325

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis

You May Also Like